139 related articles for article (PubMed ID: 34896892)
1. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
Noji R; Kano Y; Hirai H; Onishi I; Nishii N; Yoshimura R; Miyake S; Ikeda S; Harada H
Oral Oncol; 2022 Jan; 124():105666. PubMed ID: 34896892
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
3. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
[TBL] [Abstract][Full Text] [Related]
4. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
5. Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient.
Kondo T; Kawachi S; Nakatsugawa M; Takeda A; Kikawada N; Aihara Y; Okimura A; Hirano H; Ogawa Y; Tsukahara K
Auris Nasus Larynx; 2022 Aug; 49(4):721-726. PubMed ID: 33612350
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
7. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
8. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Head Neck; 2020 Nov; 42(11):3275-3281. PubMed ID: 32671898
[TBL] [Abstract][Full Text] [Related]
9. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS; Cavalieri S; Licitra L; Pistore F; Lenoci D; Canevari S; Airoldi M; Cossu Rocca M; Strojan P; Kuhar CG; Merlano M; Perrone F; Vingiani A; Denaro N; Perri F; Argiris A; Gurizzan C; Ghi MG; Cassano A; Allegrini G; Bossi P; De Cecco L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290766
[TBL] [Abstract][Full Text] [Related]
10. Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab.
Tada H; Takahashi H; Yamada K; Masuda K; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Oyama T; Tatematsu KI; Sezutsu H; Takeda S; Chikamatsu K
Cancer Immunol Immunother; 2022 Apr; 71(4):851-863. PubMed ID: 34463793
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy.
Miraki Feriz A; Bahraini F; Khosrojerdi A; Azarkar S; Sajjadi SM; HosseiniGol E; Honardoost MA; Saghafi S; Silvestris N; Leone P; Safarpour H; Racanelli V
PLoS One; 2023; 18(12):e0295863. PubMed ID: 38096229
[TBL] [Abstract][Full Text] [Related]
12. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
Okamoto I; Tsukahara K; Sato H
Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
[TBL] [Abstract][Full Text] [Related]
14. Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma.
Tada H; Takahashi H; Kawabata-Iwakawa R; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Chikamatsu K
Sci Rep; 2020 Dec; 10(1):21573. PubMed ID: 33299117
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
16. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
17. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]